Nightstar Therapeutics PLC (NITE) Given Average Recommendation of “Strong Buy” by Analysts

Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) have earned a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. Five research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price target of $30.20 for the company and are expecting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Nightstar Therapeutics an industry rank of 191 out of 265 based on the ratings given to related companies.

NITE has been the subject of several analyst reports. BMO Capital Markets initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $30.00 target price for the company. Jefferies Group initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price for the company. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 target price for the company. Leerink Swann initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $31.00 target price (up from $29.00) on shares of Nightstar Therapeutics in a research note on Wednesday, January 17th.

Shares of Nightstar Therapeutics (NITE) traded up $0.44 during mid-day trading on Tuesday, hitting $12.88. 11,600 shares of the stock traded hands, compared to its average volume of 28,073. Nightstar Therapeutics has a fifty-two week low of $11.99 and a fifty-two week high of $24.93.

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at $240,000. Nationwide Fund Advisors acquired a new stake in Nightstar Therapeutics in the third quarter valued at $1,196,000. Sphera Funds Management LTD. acquired a new stake in Nightstar Therapeutics in the third quarter valued at $1,728,000. Alyeska Investment Group L.P. acquired a new stake in Nightstar Therapeutics in the third quarter valued at $1,920,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Nightstar Therapeutics in the fourth quarter valued at $1,771,000. Institutional investors and hedge funds own 27.36% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Nightstar Therapeutics PLC (NITE) Given Average Recommendation of “Strong Buy” by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/13/nightstar-therapeutics-plc-nite-given-average-recommendation-of-strong-buy-by-analysts.html.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply